Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. It has a collaboration agreement with Oxford Performance Materials, Inc. to develop a poly-ether-ketone-ketone silicon nitride composite based on OXPEKK SC solution casting technology. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
IPO Year: 2014
Exchange: NASDAQ
Website: sintx.com
S-3 - Sintx Technologies, Inc. (0001269026) (Filer)
8-K - Sintx Technologies, Inc. (0001269026) (Filer)
424B5 - Sintx Technologies, Inc. (0001269026) (Filer)
S-8 - Sintx Technologies, Inc. (0001269026) (Filer)
S-3 - Sintx Technologies, Inc. (0001269026) (Filer)
8-K - Sintx Technologies, Inc. (0001269026) (Filer)
8-K - Sintx Technologies, Inc. (0001269026) (Filer)
10-Q - Sintx Technologies, Inc. (0001269026) (Filer)
DEF 14A - Sintx Technologies, Inc. (0001269026) (Filer)
8-K - Sintx Technologies, Inc. (0001269026) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
3 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
4 - Sintx Technologies, Inc. (0001269026) (Issuer)
Fastest customizable press release news feed in the world
Clinical evaluation of the product by design surgeons completed, driving early commercial momentum SALT LAKE CITY, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramic biomedical applications of silicon nitride (Si₃N₄), today announced the execution of a private label agreement to supply OsseoSculpt™, a next-generation biologic designed to complement the Company's FDA 510(K) cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System. Following successful evaluations by multiple design surgeons, SINTX recorded its first commercial revenue from OsseoSculpt™ in Q3 2025. OsseoSculpt features a nanocrystalline HCA s
FDA cleared and U.S. manufactured implant system positions SINTX to enter billion-dollar U.S. market SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramics specializing in biomedical applications of silicon nitride (Si₃N₄), today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX's commercial entry into reconstructive foot and ankle surgery in the United States. SINTX plans a U.S. commercial launch in Q1 2026, leveraging its U.S.-based manufacturing to drive revenue acceleration and operating efficiency. Th
New U.S. Patent reinforces competitive advantage and enables broader licensing and product opportunities across key markets SALT LAKE CITY, Utah, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application containing method claims covering the Company's antipathogenic fabric technology. This development builds upon SINTX's previously announced patent allowance for its Antipathogenic Fibrous Materials composition patent,
New method patent expands SINTX's infection-prevention IP portfolio in $30 Billion Total Addressable Market U.S. Patent Notice of Allowance reinforces competitive advantage and enables broader licensing and product opportunities across key markets SALT LAKE CITY, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application containing method claims covering the Company's antipathogenic fabric technology. This developme
SALT LAKE CITY, Utah, Sept. 09, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that it has been invited to present at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The Company's presentation is scheduled for Tuesday, September 9, 2025. "This event provides an important opportunity to share our objectives, highlight our progress, and engage directly with the institutional investor community," said Eric Olson, Chairman and
Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, "Antipathogenic Fibrous Materials." The patent secures broad protection for SINTX's proprietary silicon nitride–based antipathogen platform. This allowance marks a significant intellectual property milestone for the Company, securing broad protection for the use of silicon nitride in multiple form factors designed to neu
Company Reinforces Commercialization Focus and Strategic Direction SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission and available at www.sec.gov. The business update highlights meaningful progress from the Company's recent SiNAPTIC acquisition, decisive strategic transformation, and a revitalized commercialization strategy
SALT LAKE CITY, Utah, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for musculoskeletal applications, today announced the publication of a peer-reviewed study in the Journal of the Mechanical Behavior of Biomedical Materials. The study validates the use of silicon nitride (Si₃N₄) surface coatings on carbon fiber–reinforced polyetherketoneketone (CFR-PEKK) trauma plates—marking a significant expansion of SINTX's biomaterial platform into additively-manufactured polymer-carbon-ceramic constructs. The research, supported by the National Institute of Arthritis and Musc
Advanced Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market SALT LAKE CITY, Utah, July 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical applications, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its novel silicon nitride osteotomy wedges—marking the official entry into the foot and ankle reconstruction market. These next-generation implants blend cutting-edge biomaterials science with surgical precision and are designed to
Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t
Live Leadership Updates
Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto
Live finance-specific insights
Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t
The Acquisition Broadens Opportunities for SINTX in Aerospace, Defense, and Biomedical Markets SALT LAKE CITY, July 06, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T; https://www.techassess.com/), significantly increasing SINTX's capabilities in the aerospace, defense, and biomedical markets. "We are excited to acquire TA&T and take another step towards diversifying and strengthening SINTX," said Dr. Sonny Bal, President and CEO of SINTX. "TA&T will expand our use of advanced manufacturing techno
SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of advanced ceramics, announced today the filing of its Annual Report on Form 10-K for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. In 2021, SINTX made significant investments into the expansion of its three priority business segments - biomedical, industrial/armor, and antipathogenic - through the purchase of new technology, equipment, and personnel. The Company is narrowly focused on opportunities closest to revenue such as armor materials and plates, the development of new biomedi
SALT LAKE CITY, June 30, 2021 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ:SINT) ("SINTX" or the "Company"), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today it has moved into the next phase of its relationship with O2TODAY and sold the first shipment of FleX SN-AP antipathogenic silicon nitride powder to O2TODAY for integration into a proprietary line of masks and filters. "O2TODAY announced on its website today that it is taking limited pre-orders for masks and mask filters integrated with SINTX's antipathogenic powder," said Dr. Sonny Bal, President and CEO at SINTX Technologies. "We share th
This live feed shows all institutional transactions in real time.
SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)
SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)
SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)
SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)
SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)
SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)
SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)
SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)